Waqas Haque

Oncology fellow at the University of Chicago

[Waqas Haque @Crescent_MD]

@RoupenMD Did the study account for strict enrollment criteria? For example in prostate cancer, multiple ARPI therapies can kick people off of a lot of trials even if their oncologist or urologist switched ARPI therapies earlier in the treatment course.

[Waqas Haque @Crescent_MD]

@ShaalanBeg @chadinabhan @ShrutiPatelMD @cancerassassin1 Arguments against term limits:
1. 5 years might not be enough time to create lasting change and de-incentivizes long-term goals past one's term
2. Epic's founder has been at the helm for 47 years and I'd say they're doing pretty well!

[Ethan Mollick @emollick]

Gemini, ChatGPT & Claude: “What is the single best investment equivalent in spending $1000 that I could make if I time traveled back to any destination circa 1300.”

Gemini: Magna Carta stored at Durham Cathedral

ChatGPT: A share in Stora Kopparberg

Claude: A waqf at Al-Azhar

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

Check our viewpoint published @JAMA_current #MedEd

Abstract Factory—Research Culture Harming Medical Education

The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor.

➡️https://t.co/IMBhy45L1K

@utswcancer @rajshekharucms @HiraSMian @ManniMD1 @HemOncFellows @ASCOTECAG

[Oncology Data Advisor @OncData]

In this month’s blog, @WaqasHaqueMD explores #ASCOmind for abstract summarization (@ASCO), new recommendations for AI-powered clinical trial matching, and @Artera_io's prognostic test paving the way for personalized medicine in prostate cancer.

Read here! https://t.co/BTt2LuUlKV

[Oncology Data Advisor @OncData]

#ASCOmind is a novel #AI framework designed to help synthesize the vast amount of data presented at @ASCO meetings. Here, @WaqasHaqueMD speaks with Xiaoyan Wang, PhD (@Tulane) and @WilliamOhMD (@YaleMed) about its development and benefits.

Watch here! https://t.co/VvedysNncM

[Waqas Haque @Crescent_MD]

There's an anecdote of jurist Imam Malik (a prolific Muslim scholar from the 8th century) being grilled over 40 questions and replying "I don't know" to 36 of them -knowing what you don't know is a sign of intelligence.

[Chris @ChrisGPT]

OpenAI researcher Noam Brown on hallucination with the new IMO reasoning model:

> Mathematicians used to comb through model solutions because earlier systems would quietly flip an inequality or tuck in a wrong step, creating hallucinated answers.

> Brown says the updated IMO reasoning model now tends to say “I’m not sure” whenever it lacks a valid proof, which sharply cuts down on those hidden errors.

TLDR, the model shows a clear shift away from hallucinations and toward reliable, self‑aware reasoning.

[Muhammad Hussain, MD @whosainastro]

1/
Why is Ki-67 called Ki-67? And why am I attaching a photo of this beautiful city to the tweet?
If you work in pathology or oncology, you’ve likely come across Ki-67 many times. But where does the name come from?

A short 🧵 on the origins, function, and significance of Ki-67. #IHC #pathx #molpath

[Vivek Subbiah, MD @VivekSubbiah]

🚨 Wow! #ASCO25 @ASCO was absolutely massive!
10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

[Zunairah Shah @ZunairahShah]

The practice-changing data discussions by @OncBrothers are always a highlight of every conference! Truly enjoyed the insightful breast cancer session with Dr. Rugo @hoperugo and Dr. Jhaveri @jhaveri_komal— a masterclass in clinical relevance.

#ASCO25

[Vincent Rajkumar @VincentRK]

The fascinating story of Thalidomide: how this most notorious drug on the planet, banned in the 1960s, made an incredible comeback and revolutionized the treatment of myeloma.

I will also highlight one person whose role is not recognized: Without Dr. Leif Bergsagel there will be no thalidomide for myeloma.

Read on #MedTwitter
The thalidomide story has many takeaways and lessons.

It shows drug development from bedside to bench and back to bedside.

It shows the power and impact of astute clinicians

It shows the power of investigator courage

The role of serendipity

[Ari Rosenberg @AriRosenbergMD]

Honored to be included with such an incredible group of cancer researchers - much work remains to improve outcomes for our cancer patients.🧐🔬🧬💪

[GU Oncology Now @GUOncologyNow]

⭐ At @ASCO #GU25, a group of experts discuss their survey-based study of treatment sequencing after 1L EV/pembro for la/mUC.

📺 Sharing their insights are @PriyankaChabla1, @arkhaki, @DrKarineTawagi, and @PGrivasMDPhD: https://t.co/HPMaC3DNvt

[Waqas Haque @Crescent_MD]

Attended our basic science retreat today discussing pharma trial collaborations. While academia won't match pharma's speed, AMC's bring other strengths: translational focus, cell therapy capability, radiation and rare dz trials, tx de-escalation, and non-interventional research.

[Waqas Haque @Crescent_MD]

Ramadan Mubarak to everyone undertaking a month of fasting!

My tips for medical trainees and fellows who are trying to balance training with spiritual goals: 1) Be consistent even if it's a little, 2) keep up all your prayers (and do extra at night), and 3) read Quran daily.

[Waqas Haque @Crescent_MD]

Have an interesting #oncology #clinical case or management dilemma? Submit it on Primum -- the best case within our two categories (1: attendings, 2: trainees -- students/residents/fellows) will get a cash prize, certificate, and have the case addressed by a mini tumor board.